For research use only. Not for therapeutic Use.
Sabutoclax, also known as BI-97C1, is a potent a Mcl-1 Antagonist. Sabutoclax inhibits Tumorigenesis in Transgenic Mouse and Human Xenograft Models of Prostate Cancer. Sabutoclax (BI97C1) induce mitochondrial fragmentation either upstream of or independent of apoptosis.
| Catalog Number | R061522 |
| CAS Number | 1228108-65-3 |
| Synonyms | BI 97C1; (1R)-1,1’,6,6’,7,7’-Hexahydroxy-3,3’-dimethyl-N5,N5’-bis[(2R)-2-phenylpropyl]-[2,2’-binaphthalene]-5,5’-dicarboxamide |
| Molecular Formula | C42H40N2O8 |
| Purity | ≥95% |
| Target | Bcl-2 Family |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| IUPAC Name | 2,3,5-trihydroxy-7-methyl-N-[(2R)-2-phenylpropyl]-6-[1,6,7-trihydroxy-3-methyl-5-[[(2R)-2-phenylpropyl]carbamoyl]naphthalen-2-yl]naphthalene-1-carboxamide |
| InChI | InChI=1S/C42H40N2O8/c1-21-15-27-29(17-31(45)39(49)35(27)41(51)43-19-23(3)25-11-7-5-8-12-25)37(47)33(21)34-22(2)16-28-30(38(34)48)18-32(46)40(50)36(28)42(52)44-20-24(4)26-13-9-6-10-14-26/h5-18,23-24,45-50H,19-20H2,1-4H3,(H,43,51)(H,44,52)/t23-,24-/m0/s1 |
| InChIKey | RAYNZUHYMMLQQA-ZEQRLZLVSA-N |
| SMILES | CC1=C(C(=C2C=C(C(=C(C2=C1)C(=O)NCC(C)C3=CC=CC=C3)O)O)O)C4=C(C=C5C(=C4O)C=C(C(=C5C(=O)NCC(C)C6=CC=CC=C6)O)O)C |
| Reference | </br>1:Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM.Neoplasia. 2013 May;15(5):568-78. PMID: 23633928 Free PMC Article</br>2:Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Jackson RS 2nd, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, Bhowmick NA.Neoplasia. 2012 Jul;14(7):656-65. PMID: 22904682 Free PMC Article</br>3:Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB.J Cell Physiol. 2012 May;227(5):2145-53. doi: 10.1002/jcp.22947. PMID: 21780116 Free PMC Article</br>4:Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB.Proc Natl Acad Sci U S A. 2011 May 24;108(21):8785-90. doi: 10.1073/pnas.1100769108. Epub 2011 May 9. PMID: 21555592 Free PMC Article |
